^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MEDI-570

    i
    Other names: MEDI-570, MEDI570, MEDI 570
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    ICOS inhibitor
    Associations

    News

    Trials
    2ms
    Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    MEDI-570
    1year
    Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD4 (CD4 Molecule)
    |
    MEDI-570
    almost2years
    Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, National Cancer Institute (NCI) | N=38 --> 21 | Trial completion date: Dec 2023 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Aug 2023
    Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
    |
    CD4 (CD4 Molecule)
    |
    MEDI-570
    almost3years
    Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma. (PubMed, Clin Cancer Res)
    MEDI-570 was well tolerated and showed promising clinical activity in refractory AITL. MEDI-570 resulted in sustained reduction of ICOS+ T lymphocytes.
    Journal
    |
    CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator)
    |
    MEDI-570
    3years
    Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma (clinicaltrials.gov)
    P1, N=38, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    MEDI-570
    4years
    Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma (clinicaltrials.gov)
    P1, N=38, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    MEDI-570
    almost5years
    Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma (clinicaltrials.gov)
    P1, N=38, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    MEDI-570
    over5years
    [VIRTUAL] A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930) (ASH 2020)
    MEDI-570 was safe, well tolerated and showed promising clinical activity in poor-risk refractory and heavily pretreated AITL. A RP2D was established. MEDI-570 results in sustained reduction of the targeted ICOS+T lymphocytes.
    P1 data
    |
    ICOS (Inducible T Cell Costimulator)
    |
    MEDI-570